Premium
Flow cytometric minimal residual disease assessment in B‐cell precursor acute lymphoblastic leukaemia patients treated with CD19‐targeted therapies — a EuroFlow study
Author(s) -
Verbeek Martijn W. C.,
Buracchi Chiara,
Laqua Anna,
Nierkens Stefan,
Sedek Lukasz,
FloresMontero Juan,
Hofmans Mattias,
Sobral de Costa Elaine,
Nováková Michaela,
Mejstrikova Ester,
Barrena Susana,
Kohlscheen Saskia,
Szczepanowski Monika,
Kulis Jan,
Oliveira Elen,
Jugooa Romana,
Jong Anja X.,
Szczepanski Tomasz,
Philippé Jan,
Dongen Jacques J. M.,
Orfao Alberto,
Brüggemann Monika,
Gaipa Giuseppe,
Velden Vincent H. J.
Publication year - 2022
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.17992
Subject(s) - minimal residual disease , medicine , cd19 , immunophenotyping , oncology , flow cytometry , immunology , leukemia
Summary The standardized EuroFlow protocol, including CD19 as primary B‐cell marker, enables highly sensitive and reliable minimal residual disease (MRD) assessment in B‐cell precursor acute lymphoblastic leukaemia (BCP‐ALL) patients treated with chemotherapy. We developed and validated an alternative gating strategy allowing reliable MRD analysis in BCP‐ALL patients treated with CD19‐targeting therapies. Concordant data were obtained in 92% of targeted therapy patients who remained CD19‐positive, whereas this was 81% in patients that became (partially) CD19‐negative. Nevertheless, in both groups median MRD values showed excellent correlation with the original MRD data, indicating that, despite higher interlaboratory variation, the overall MRD analysis was correct.